Clinical Trials Logo

Basal Cell Carcinoma (BCC) clinical trials

View clinical trials related to Basal Cell Carcinoma (BCC).

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT02144077 Completed - Clinical trials for Basal Cell Carcinoma (BCC)

Safety and Efficacy Study for the Treatment of Non-Aggressive Basal Cell Carcinoma With Photodynamic Therapy

Start date: January 28, 2014
Phase: Phase 3
Study type: Interventional

The aim of this study is to test the effectiveness and safety of the medicine Ameluz® (5-aminolevulinic acid) in comparison to methyl-aminolevulinate (MAL), used with photodynamic therapy (PDT), to treat thin, non-aggressive BCC (basal cell carcinoma).

NCT ID: NCT01108094 Completed - Skin Cancer Clinical Trials

Pilot Biomarker Trial to Evaluate the Efficacy of Itraconazole in Patients w/ Basal Cell Carcinomas

Start date: April 2010
Phase: Phase 2
Study type: Interventional

Basal cell carcinomas (BCCs) are the most common human cancer in the US and affect over 1 million people. There is no effective drug to prevent basal cell carcinomas of the skin. We hope to learn if an oral anti-fungal drug, itraconazole, might inhibit a marker of proliferation and a biomarker (tumor signaling pathway) of BCC development. Itraconazole is an FDA-approved drug for the treatment of fungal infections of the skin, and has been used for the past 25 years with relatively few side effects. It has been shown in mice to reduce a BCC biomarker and to reduce growth of BCCs. Thus, it may reduce BCC growth in humans.

NCT ID: NCT00670189 Completed - Clinical trials for Basal Cell Carcinoma (BCC)

A Phase 1 Study of BMS-833923 (XL139) in Subjects With Advanced or Metastatic Cancer

Start date: July 2008
Phase: Phase 1
Study type: Interventional

The purpose of this study is to determine the safety of BMS-833923 (XL139) in patients with advanced or metastatic cancers and determine the recommended phase 2 dose range and schedule